Tobacco and Vapes Bill (Tenth sitting)

Tristan Osborne Excerpts

Committee stage
Tuesday 21st January 2025 Public Bill Committees

[Dr Johnson]

I thank my hon. Friend for his question. I guess that some of that will come under the regulations that the Minister would produce under this clause. The products are defined as tobacco products, tobacco-related devices, herbal smoking products, cigarette papers, vaping products and nicotine products, so I guess anything that falls into those categories would need to be registered. However, as we have seen already, simply registering a product does not necessarily say that it is safe, or even necessarily guarantee that it contains what it says it contains. It is potentially helpful to have the ingredients, to know what people have consumed, but having something registered with the MHRA may suggest to some consumers that there is a safety check that has not been done here.

[Tristan Osborne]

In relation to the MHRA, we know from our brief look at the data that one in three products contains impurities. That is data that is currently provided. We absolutely accept that we need a robust regulatory environment. Is the shadow Minister suggesting that the regulator should, or should not, be the MHRA, in this case?

[Dr Johnson]

I am suggesting that there is a difference between regulating a product as a medicine, which requires stringent steps, and a statement of what the product does, the effect it is going to have on the body, the claims made about it, and why it is safe, or safer than having the problem that it is treating. Some drugs make people quite unwell but people are willing to trade off being unwell for being cured. For example, cancer drugs make people very poorly at times, but it is considered better to have chemotherapy than cancer, because cancer leads to fatality. That process lets a consumer know that the product has been robustly tested and that the quality is there. On an ongoing basis, someone is checking that the paracetamol bought from a supermarket contains the ingredients that it says it contains on the packet. This notification process does not do that. It says to a company, “Come along and tell us what’s in it. We’ll believe you. Thank you very much. We’re not going to check and we’ll hope it’s all right.” That is a weak process.

It is not surprising that there is a weaker process for a consumer product than for a medical product. However, having it also done by the MHRA could lead consumers to believe that the vapes have gone through the first process and not the second process. I think that is misleading—some of the Minister’s hon. Friends are nodding vigorously—and was something brought up by the MHRA itself in response to, I think, my question. The MHRA answered that this could mislead consumers to think that it is medical regulation of vapes when it is not. There is only a point in having a register if it will be used to achieve something. Having a list of stuff does not make a great deal of difference if no one is going to check that the list is accurate, and I cannot see that there is any great step to say that the list is accurate. What comes with a register is important, as well as the register itself.

The rationale, as I understand it, of the register is to support the compliant market by having products registered and shown to be meeting the regulations. Again, I understand that this registers that a company has said that it complies with the regulations but I cannot see where the provisions say that there is anyone checking. That may be something that the Minister will add, maybe in relation to later clauses.

The aim of the register is to help to ensure legitimate products are available for sale, and to let retailers know what they are. When a retailer—a chap running a corner shop—wants to buy some of these products to sell, and he has a licence, and he has checked people’s ages under the provisions of the earlier clauses, and he wants to sell the product, he wants reassurance that the product is genuine and not illicit. Checking this register for that product would be a step that a reasonable retailer can take to check the product is legit, or at least said to be legit.

Both industry and enforcement agencies have asked the Government to update the current notification systems. Although that was not part of the consultation process, I understand—and the Minister can perhaps clarify this—that subsequent consultation will be required to better inform the new registration system and its implementation.

The Government would like to ensure that non-nicotine vapes and other nicotine products being sold in the UK market are subject to the current notification requirements of nicotine vapes. That is in line with the consultation undertaken by the previous Government in 2023, when the majority of responses were in favour of regulating all non-nicotine vapes and other nicotine products under a similar regulatory framework as nicotine vapes. Again, I ask the Minister to consider whether the MHRA is the best organisation to be providing that service if it is not doing what most of the public may consider it is doing?

At the moment, if enforcement agencies find that the product is notified as not being compliant with regulations, they are unable to update the notification accordingly. The new powers will ensure that the register of products can be updated, and therefore that items can be removed if they are not meeting requirements. To ensure that we can effectively monitor the products and support enforcement, it is necessary for the Government to have the power to introduce the registration regime. I am not against the principle of that, but I think it needs to be well thought through. Perhaps it will be when it comes to the regulations in the statutory instrument—when we no doubt meet again. Adding regulations in general is not necessarily a welcome thing, but in that case it may be useful.

There will be some costs to industry, due to measures including product registration requirements, particularly on non-nicotine vapes and other nicotine products. That may put off producers with lower standards and may improve the general safety standard of the industry, but it is also possible that those with lower standards will not bother, so the Minister needs to explain what the plan is for that—and also the plans for factories.

The registration requirements will also mean that consumers can access more information on non-nicotine vapes and other nicotine products. I ask the Minister: will consumers have access to the information on what all the ingredients are? Will there be thought given to people with allergies who wish to use those products? There may be a cost to companies that have to request information from their suppliers and gather existing data on non-nicotine vapes and other nicotine products. Companies will also have to spend resources on completing the required paperwork.

Based on the impact assessment for the Tobacco and Related Products Regulations, I understand that the Government expect those tasks to take between 10 and 15 hours per notification, plus or minus any translations or translation costs that may be required. Given that any companies notifying the UK will be selling or operating in the UK, translation costs should be negligible. Therefore, it will be 10 to 15 hours work, plus currently a small fee of £150 to notify of a nicotine-containing vape product. There is also a fee for tobacco and herbal products set at £200, a fee for any modifications at £100, and a further annual reporting fee of £100.

A new fee will be imposed to register products, which will likely be in line with the current fees for tobacco, herbal and nicotine-vape products. Non-nicotine vape products and other nicotine products that were not subject to notification of fees will be charged a fee to register, with the amount to be determined through further consultation. That is another case where essentially what is happening is that the Government are taking a lot of power to do things, but not being terribly explicit about what they intend to do with them. While the Minister said that he is going to go like the clappers, we still have no clear indication of how fast those clappers are clapping away.

For potential new information requirements, there may be additional costs with acquiring that information. Some manufacturers may already collect new information, in which case there will be no additional costs other than staff time spent collating and submitting. Those costs may be more burdensome for smaller companies. The changes will be achieved through secondary legislation, which will be subject to consultation to determine what information should be notified, how the registration will operate, the process for any non-publication of notification and the level of fees associated with costs administering the system.

The impact assessment says that the Bill will also give the industry enough time for businesses to make any changes before the future regulations come into force. Again, the Government are saying that they are going to give enough time, and they are going to go like the clappers. But how fast are the clappers going and how much time is enough for industry? I still do not think we have any idea.

I have a couple of questions. In subsection (3)(a), where the regulations make a provision about who is to keep the register, will the Government clarify what that Government body or third-party private entity will be? Will it be the MHRA, or will it be something else?

Subsection (3)(b) gives the Secretary of State power to regulate eligibility for registration. There is room for debate about what constitutes eligibility and whether small businesses or new entrants will face excessive regulatory hurdles. The power may also raise concerns about what happens if a product or business fails to meet the requirements. Will they be shut out of the market? Will they be forced to make changes? How will that work?

Paragraphs (c) and (d) of subsection (4) require producers to provide information about potential risks to human health and substances released by products, but the wording is relatively broad and could raise questions about how tobacco and nicotine product manufacturers will assess and report risks. What level of scientific evidence will be required? How will they balance transparency with proprietary information or concerns about trade secrets? What will happen if the product risk assessment is disputed, and how will disputes be resolved?

We may have a situation where the vape manufacturer says that their product and the flavourings are safe but the evidence from medical professionals suggests otherwise. Will they provide the information themselves or will they fund other people to do it? Will that be done under a general pool, or will it be specific to that product at that time? How much influence will the industry have over the results? If we ask a specific question, we will get closer to the answer we want.

In the case of vaping products specifically, the health risks are not yet fully known. It is fair to say that there is some debate on the matter, even among respected authorities. The American Lung Association claims that vaping is linked to a condition called popcorn lung, and the Harvard Medical School lists popcorn lung under the risks of vaping. However, the NHS and Cancer Research assert that vaping does not cause popcorn lung, so there is a dispute. Clearly, more research is needed, but in the meantime how will the regulations in the clause address an issue like this?

Subsection (5) introduces the idea of fees for registration, including provisions that allow the fees collected to reflect the cost of regulation. It raises issues about how the fees may affect small and independent producers in a market that is taxed. Do we have any indication about what the fees may be? Could the cost of registration become prohibitive for small companies and push them out of the market? Will there be mechanisms to ensure that the fees are not too burdensome for newer and small businesses, or is the intention to limit the number of products on the market by making the fees higher so that we get a smaller number of products and are therefore more able to regulate and assess what is in each of them?